What Cancers Does Methotrexate Treat?

Methotrexate stands as a fundamental anticancer medication which oncologists use in their practice today. The treatment method which doctors developed many years ago remains essential for multiple cancer types because doctors use it to start patient care or combine it with other medications. Methotrexate shows clinical value in cancer therapy because it treats various cancer types and medical professionals still use this medication in their practice.

The article provides an evidence-based review of methotrexate-treated cancers which focuses on treatment principles instead of basic drug information.

Understanding Methotrexate's Role in Cancer Therapy

Figure 1. Cellular transport of glucose–methotrexate conjugate (GLU–MTX) in healthy and cancer cells with GLUT1 overexpression. (Source: Woźniak M, et al.; 2021)

Methotrexate is an antimetabolite and antifolate agent. The compound blocks DNA synthesis and repair and cell replication through its ability to stop dihydrofolate reductase enzyme function which cells need to make nucleotides. The fast cell division of cancer cells creates their most vulnerable point because their abnormal growth patterns become easily disrupted.

Solid Tumors Responsive to Methotrexate

Osteosarcoma

Methotrexate plays a major role in the treatment of osteosarcoma, especially in children and adolescents.

High-dose methotrexate, combined with:

• Doxorubicin
• Cisplatin

The new treatment methods have resulted in better patient survival outcomes which now enable patients to live longer. The medical team performs strict monitoring of methotrexate treatment while using leucovorin rescue to minimize side effects while preserving its ability to fight cancer cells.

Breast Cancer

Methotrexate has historically been used in early-stage and metastatic breast cancer, particularly as part of combination chemotherapy regimens such as:

• CMF

While newer agents have reduced its frontline use, methotrexate remains relevant in:

• Selected low-resource settings
• Hormone receptor–positive disease when other therapies are unsuitable

Head and Neck Cancers

Methotrexate is used in squamous cell carcinomas of the head and neck, particularly in:

• Recurrent disease
• Palliative settings

Skin and Soft Tissue Malignancies

Cutaneous T-Cell Lymphoma (CTCL)

Low-dose methotrexate is commonly prescribed for cutaneous T-cell lymphoma, especially early-stage disease.

Benefits include:

• Disease control
• Symptom relief (itching, skin lesions)
• Oral administration with manageable toxicity

Soft Tissue Sarcomas

Methotrexate has shown activity in selected sarcoma subtypes, often as part of multi-agent chemotherapy, though its use is less common than in osteosarcoma.

Why Methotrexate Remains Clinically Relevant

Despite the rise of targeted therapies and immuno-oncology, methotrexate continues to be used because it offers:

• Proven long-term clinical outcomes
• Cost-effectiveness
• Versatility across cancer types
• Compatibility with combination regimens

Its pharmacology is well understood, allowing clinicians to optimize dosing, toxicity management, and supportive care strategies.

The Future of Methotrexate in Oncology

Future research directions for methotrexate mainly include:

• Optimized dosing strategies
• Novel delivery systems
• Combination therapies that enhance efficacy while reducing toxicity

The research into new medical approaches shows that this well-known drug offers extra therapeutic benefits to patients.

FAQ

Methotrexate Antibodies

Methotrexate Antigen

Methotrexate ELISA